Trial results

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042 on ClinicalTrials.gov · last registry update 2026-07-16

An unusually large phase 2: 326 participants, more than double the 114 typical for the stage. The sponsor logged completion for 27 February 2026. Primary outcome, as filed: Primary Objective. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Gan and Lee Pharmaceuticals, USA

Sponsor type

Industry

Enrollment

326

Started

2025-02-24

Primary completion

2026-02-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Primary Objective

Conditions studied

Obesity and Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.